Allogene Therapeutics (ALLO)CEO sold ~$77K

~$77K

Approx. value · 46K sh @ $1.68

5.32M

Holds after · shares reported

Traded

Feb 3, 2025

Filed

Feb 5, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Dec 5, 2024InsiderDirector sold ~$20K of ALLO shares in the open market
2. Dec 9, 2024InsiderDirector sold ~$20K of ALLO shares in the open market
3. Jan 21, 2025InsiderOfficer sold ~$48K of ALLO shares in the open market
4. Feb 3, 2025 · this disclosureInsiderCEO sold ~$77K of ALLO shares in the open market

What came next

1. Feb 3, 2025Insider · 4 peopleInsiders: 4 sales (~$76K)
2. Feb 18, 2025InsiderDirector sold ~$32K of ALLO shares in the open market
3. Mar 14, 2025Insider · 2 peopleInsiders: 2 sales (~$102K)
4. Apr 21, 2025InsiderOfficer sold ~$14K of ALLO shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Allogene Therapeutics

For Allogene Therapeutics, OQRO holds 1 insider filing (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ALLO page.

Other recent filings by David D Chang, President and CEO

• SEC Form 4 at Allogene Therapeutics (ALLO)Mar 18, 2026
• SEC Form 4 at Allogene Therapeutics (ALLO)Feb 4, 2026
• SEC Form 4 at Allogene Therapeutics (ALLO)Mar 18, 2025

The full history of David D Chang, President and CEO is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Allogene Therapeutics

• SEC Form 4Aug 25, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 4Apr 23, 2026
• SEC Form 4Apr 2, 2026
• SEC Form 4Mar 18, 2026
• SEC Form 4Mar 18, 2026

Everything OQRO holds on this company is on its ALLO page.